Ru Xin Wong, Radiation Oncologist at Proton Therapy SG, shared a post on LinkedIn:
“Google NotebookLM can summarise articles and create podcasts for listening on the go!
NSABP B-51 NEJM June 2025
Insights!
Who was included?
- Patients initially had clinical stage T1-T3, N1, M0 breast cancer
- Crucially, all axillary nodes had to be ypN0 after surgery
- Randomisation > regional nodal RT or none
- Population had a higher representation of HER2-positive (56.7%) and triple-negative (22.3%) cancers, reflecting their higher pathological response rates to neoadjuvant therapy.
Key Findings (by subtype):
- Overall: RNI did NOT significantly improve the recurrence-free interval.
- Triple-negative breast cancer: Suggested a potential greater risk of recurrence with RNI (HR 2.30). This finding is ‘hard to explain’.
- HR-positive and HER2-negative breast cancer: Indicated a potential benefit from RNI (HR 0.41) [7, 9]. Longer follow-up essential.
- Other HER2-positive subtypes (HR-negative and HR-positive): No clear signal for benefit or harm was observed
Important Note: Subgroup analyses were exploratory with wide confidence intervals.”
More posts featuring Ru Xin Wong.